Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Key Points: PVD is an active combination in relapsed lenalidomide-refractory MM patients. PVD with weekly bortezomib offers a simpler, more convenient, and well-tolerated regimen option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Self-citationRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citationLopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Self-citationEfficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381
Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348896 · Cited by 222
Self-citation
Research works printed but not linked: 19
- Kyle, 2008, Multiple myeloma, Blood, 111, 2962, 10.1182/blood-2007-10-078022 · DOI · Paper page
- Manier, 2012, Bone marrow microenvironment in multiple myeloma progression, 10.1155/2012/157496 · DOI · Paper page
- Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
- Quach, 2010, Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma, Leukemia, 24, 22, 10.1038/leu.2009.236 · DOI · Paper page
- Kawano, 2015, Targeting the bone marrow microenvironment in multiple myeloma, Immunol Rev, 263, 160, 10.1111/imr.12233 · DOI · Paper page
- Rychack, 2011, Overcoming resistance; the use of pomalidomide and dexamethasone in re-sensitizing lenalidomide-resistant multiple myeloma cells, Haematologica, 96, 126
- Richardson, 2012, MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma, Blood, 120, 727, 10.1182/blood.V120.21.727.727 · DOI
- Palumbo, 2014, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival, J Clin Oncol, 32, 634, 10.1200/JCO.2013.52.0023 · DOI · Paper page
- Kyle, 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
- Rychak, 2016, Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma, Br J Haematol, 172, 889, 10.1111/bjh.13905 · DOI · Paper page
- San Miguel, 2013, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 1055, 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
- Ocio, 2015, In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone, Leukemia, 29, 705, 10.1038/leu.2014.238 · DOI · Paper page
- Richardson, 2014, A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma, Blood, 123, 1461, 10.1182/blood-2013-07-517276 · DOI · Paper page
- Durie, 2015, Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777, Blood, 126, 25, 10.1182/blood.V126.23.25.25 · DOI · Paper page
- Verma, 2015, Identification of a cereblon-independent protein degradation pathway in residual myeloma cells treated with immunomodulatory drugs, Blood, 126, 913, 10.1182/blood.V126.23.913.913 · doi:10.1182/blood.v126.23.913.913
- Shah, 2015, Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma, Blood, 126, 2284, 10.1182/blood-2015-05-643320 · DOI · Paper page
- Palumbo, 2016, Daratumumab, bortezomib, and dexamethasone for multiple myeloma, N Engl J Med, 375, 754, 10.1056/NEJMoa1606038 · DOI · Paper page
- Reeder, 2010, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma, Blood, 115, 3416, 10.1182/blood-2010-02-271676 · DOI · Paper page
- Leleu, 2013, Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02, Blood, 121, 1968, 10.1182/blood-2012-09-452375 · DOI · Paper page
Cited by
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga, A., Ay, C., Di Nisio, M., Gerotziafas, G., Jara-Palomares, L., Langer, F., Lecumberri, R., Mandala, M., Maraveyas, A., Pabinger, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.014 · Cited by 413
Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citationThe proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Self-citationChim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305
Self-citationMateos, M.-V., Blacklock, H., Schjesvold, F., Oriol, A., Simpson, D., George, A., Goldschmidt, H., Larocca, A., Chanan-Khan, A., Sherbenou, D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30110-3 · Cited by 257
Self-citation
Metadata
- Authors
- Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., Kapoor, P., Leung, N., Russell, S. J., Dingli, D., Go, R. S., Lin, Y., Gonsalves, W. I., Fonseca, R., Bergsagel, P. L., Roy, V., Sher, T., Chanan-Khan, A. A., Ailawadhi, S., Stewart, A. K., Reeder, C. B., Richardson, P. G., Rajkumar, S. V., & Lacy, M. Q.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-09-07
- Volume
- 130
- Issue
- 10
- Pages
- 1198-1204
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2512928744
- Cited by
- 78
- References
- 8
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2017-05-782961
- The paper
- Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., Kapoor, P., Leung, N., Russell, S. J., Dingli, D., Go, R. S., Lin, Y., Gonsalves, W. I., Fonseca, R., Bergsagel, P. L., . . . Lacy, M. Q. (2017). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2017-05-782961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.